Patents by Inventor Kevin N. Sill

Kevin N. Sill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10836869
    Abstract: The present disclosure relates to the field of polymer chemistry and more particularly to multiblock copolymers comprising a poly(sarcosine) block and a D,L-mixed poly(amino acid) block and uses thereof.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: November 17, 2020
    Assignee: Tyndall Formulation Services, LLC
    Inventors: Kevin N. Sill, Bradford T. Sullivan
  • Publication number: 20200002376
    Abstract: The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.
    Type: Application
    Filed: June 24, 2019
    Publication date: January 2, 2020
    Inventors: ROBERT J. GILLIES, DAVID L. MORSE, NATALIE M. BARKEY, KEVIN N. SILL, JOSEF VAGNER, NARGES K. TAFRESHI, JONATHAN L. SESSLER, CHRISTIAN PREIHS, VICTOR J. HRUBY
  • Publication number: 20190321353
    Abstract: The present invention provides SN-38 compositions for treating cancer.
    Type: Application
    Filed: November 19, 2018
    Publication date: October 24, 2019
    Inventors: Kevin N. Sill, Adam Carie
  • Patent number: 10329326
    Abstract: The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: June 25, 2019
    Assignees: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM, H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., INTEZYNE TECHNOLOGIES INC.
    Inventors: Robert J. Gillies, David L. Morse, Natalie M. Barkey, Kevin N. Sill, Josef Vagner, Narges K. Tafreshi, Jonathan L. Sessler, Christian Preihs, Victor J. Hruby
  • Patent number: 10143689
    Abstract: The present invention provides SN-38 compositions for treating cancer.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: December 4, 2018
    Assignee: Interzyne Technologies, Inc.
    Inventors: Kevin N. Sill, Adam Carie
  • Publication number: 20180228796
    Abstract: The present invention provides SN-38 compositions for treating cancer.
    Type: Application
    Filed: February 8, 2018
    Publication date: August 16, 2018
    Inventors: Kevin N. Sill, Adam Carie
  • Publication number: 20170218017
    Abstract: The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.
    Type: Application
    Filed: September 12, 2016
    Publication date: August 3, 2017
    Inventors: ROBERT J. GILLIES, DAVID L. MORSE, NATALIE M. BARKEY, KEVIN N. SILL, JOSEF VAGNER, NARGES K. TAFRESHI, JONATHAN L. SESSLER, CHRISTIAN PREIHS, VICTOR J. HRUBY
  • Patent number: 9441013
    Abstract: The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.
    Type: Grant
    Filed: May 17, 2012
    Date of Patent: September 13, 2016
    Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., INTEZYNE TECHNOLOGIES INC, ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM
    Inventors: Robert J. Gillies, David L. Morse, Natalie M. Barkey, Kevin N. Sill, Josef Vagner, Narges K. Tafreshi, Jonathan L. Sessler, Christian Preihs, Victor J. Hruby
  • Publication number: 20150232616
    Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same.
    Type: Application
    Filed: February 5, 2015
    Publication date: August 20, 2015
    Inventors: Kevin N. Sill, Habib Skaff, Kurt Breitenkamp
  • Patent number: 8980326
    Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same.
    Type: Grant
    Filed: September 1, 2010
    Date of Patent: March 17, 2015
    Assignee: Intezyne Technologies, Inc.
    Inventors: Kevin N. Sill, Habib Skaff, Kurt Breitenkamp
  • Patent number: 8779008
    Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: July 15, 2014
    Assignee: Intezyne Technologies, Inc.
    Inventors: Kurt Breitenkamp, Kevin N. Sill, Habib Skaff, Rebecca Breitenkamp
  • Publication number: 20140170225
    Abstract: The present invention relates to the field of polymer chemistry and more particularly to encapsulated peptides and uses thereof.
    Type: Application
    Filed: August 1, 2013
    Publication date: June 19, 2014
    Inventors: CHUANHAI CAO, XIAOYANG LIN, KURT BREITENKAMP, HABIB SKAFF, KEVIN N. SILL
  • Patent number: 8747904
    Abstract: The present invention provides micelles having a polynucleotide encapsulated therein, the micelle comprising copolymers comprising hydrophobic moieties in a cationic complexing block. The invention further provides methods of preparing and using said micelles, and compositions thereof.
    Type: Grant
    Filed: August 21, 2012
    Date of Patent: June 10, 2014
    Assignee: Intezyne Technologies, Inc.
    Inventors: Janni Mirosevich, Gregoire Cardoen, Kevin N. Sill, Habib Skaff
  • Publication number: 20140112873
    Abstract: The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.
    Type: Application
    Filed: May 17, 2012
    Publication date: April 24, 2014
    Applicants: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM, ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, INTEZYNE TECHNOLOGIES INC.
    Inventors: Robert J. Gillies, David L. Morse, Natalie M. Barkey, Kevin N. Sill, Josef Vagner, Narges K. Tafreshi, Jonathan L. Sessler, Christian Preihs, Victor J. Hruby
  • Patent number: 8629186
    Abstract: The present invention provides micelles having an anthracycline encapsulated therein, the micelles comprising a multiblock copolymer. The invention further provides methods of preparing and using said micelles, and compositions thereof.
    Type: Grant
    Filed: July 25, 2013
    Date of Patent: January 14, 2014
    Assignee: Intezyne Technologies, Inc.
    Inventors: Kevin N. Sill, Habib Skaff, Jonathan Rios-Doris
  • Publication number: 20130344117
    Abstract: The present invention provides polymers, compositions thereof, and polyplexes comprising said polymers. In particular, cationic polymers, pegylated versions thereof, and polynucleotide containing polyplexes comprising such polymers are provided. The invention further provides methods of using said polymers and polyplexes.
    Type: Application
    Filed: March 13, 2013
    Publication date: December 26, 2013
    Applicant: INTEZYNE TECHNOLOGIES, INC
    Inventors: Janni Mirosevich, Kevin N. Sill, Gregoire Cardoen
  • Publication number: 20130310912
    Abstract: The present invention provides modified metal surfaces, methods of preparing the same, and intermediates thereto. These materials are useful in a variety of applications including biomaterials.
    Type: Application
    Filed: July 22, 2013
    Publication date: November 21, 2013
    Applicant: Intezyne Technologies
    Inventors: Kurt Breitenkamp, Rebecca Breitenkamp, Kevin N. Sill, Habib Skaff
  • Publication number: 20130309277
    Abstract: The present invention provides micelles having an anthracycline encapsulated therein, the micelles comprising a multiblock copolymer. The invention further provides methods of preparing and using said micelles, and compositions thereof.
    Type: Application
    Filed: July 25, 2013
    Publication date: November 21, 2013
    Applicant: Intezyne Technologies, Incorporated
    Inventors: Kevin N. Sill, Habib Skaff, Jonathan Rios-Doria
  • Publication number: 20130266617
    Abstract: The present invention provides micelles having a polynucleotide encapsulated therein, the micelle comprising copolymers comprising hydrophobic moieties in a cationic complexing block. The invention further provides methods of preparing and using said micelles, and compositions thereof.
    Type: Application
    Filed: August 21, 2012
    Publication date: October 10, 2013
    Applicant: Intezyne Technologies, Inc.
    Inventors: Janni Mirosevich, Gregoire Cardoen, Kevin N. Sill, Habib Skaff
  • Patent number: 8524784
    Abstract: The present invention provides micelles having an anthracycline encapsulated therein, the micelles comprising a multiblock copolymer. The invention further provides methods of preparing and using said micelles, and compositions thereof.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: September 3, 2013
    Assignee: Intezyne Technologies, Incorporated
    Inventors: Kevin N. Sill, Habib Skaff, Jonathan Rios-Doria